Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ therapeutic use
Bevacizumab
/ therapeutic use
Female
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema
/ diagnostic imaging
Male
Middle Aged
Prospective Studies
Receptors, Vascular Endothelial Growth Factor
/ therapeutic use
Recombinant Fusion Proteins
/ therapeutic use
Retinal Vein Occlusion
/ diagnostic imaging
Subretinal Fluid
Tomography, Optical Coherence
Visual Acuity
/ physiology
Anti-VEGF
Macular edema
Retinal vein occlusion
Spectral domain OCT
Visual acuity
Journal
Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
16
09
2020
revised:
07
12
2020
accepted:
21
12
2020
pubmed:
30
12
2020
medline:
8
1
2022
entrez:
29
12
2020
Statut:
ppublish
Résumé
To evaluate the association between baseline demographic and spectral domain OCT (SD-OCT) features with visual acuity (VA) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) over 2 years. Post hoc analysis of prospective clinical trial data. A total of 362 SCORE2 participants with macular edema secondary to central retinal (CRVO) or hemiretinal vein occlusion (HRVO). Spectral domain OCT volume scans were assessed at the SCORE2 reading center at baseline, month 01 (M01), month 06 (M06), month 12 (M12), and month 24 (M24) for central subfield thickness (CST), subretinal fluid, intraretinal fluid, vitreoretinal interface abnormalities, disorganization of retinal inner layers (DRIL), and ellipsoid zone (EZ) within the central subfield (CSF). Visual acuity at M06, M12, and M24. Mean baseline age was 68.9 years. Mean VA at M01 was 63.2 letters, and CST was 299.7 μm. At M01, subretinal fluid was seen in 28.5% intraretinal fluid in 67.2%, DRIL was seen in 73.8%, mostly within the CSF, and the EZ was absent in 9.8 and patchy in 31.7%. In multivariate analysis including all M01 demographics and SD-OCT parameters and their association with VA at M06, M12, and M24, VA at M01 remained significant across all time points up to M24 (P < 0.001). In this 2-year follow-up of eyes that were treated with both per protocol and off protocol for RVO, VA at M01 was an important predictor of long-term vision and change in vision. Establishing predictors of visual recovery helps identify causes for poor responders to treatment in patients with RVO.
Identifiants
pubmed: 33373715
pii: S2468-6530(20)30503-0
doi: 10.1016/j.oret.2020.12.016
pmc: PMC8233398
mid: NIHMS1658181
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Bevacizumab
2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Types de publication
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
991-998Subventions
Organisme : NEI NIH HHS
ID : P30 EY016665
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023533
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023529
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023521
Pays : United States
Organisme : NEI NIH HHS
ID : UG1 EY023533
Pays : United States
Informations de copyright
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Références
Ophthalmology. 2010 Jun;117(6):1124-1133.e1
pubmed: 20381871
JAMA Ophthalmol. 2017 Jun 1;135(6):639-649
pubmed: 28492860
BMC Ophthalmol. 2019 Jan 8;19(1):11
pubmed: 30621653
Retina. 2017 Sep;37(9):1710-1722
pubmed: 27984548
Ophthalmology. 2017 Feb;124(2):245-256
pubmed: 27863843
Ophthalmology. 2010 Jun;117(6):1094-1101.e5
pubmed: 20430447
JAMA Ophthalmol. 2019 Jan 1;137(1):38-46
pubmed: 30286219
Ophthalmol Retina. 2020 Jan;4(1):67-76
pubmed: 31669329
Am J Ophthalmol. 2017 Oct;182:160-167
pubmed: 28837790
Ophthalmology. 2009 Mar;116(3):504-12
pubmed: 19167078
Ophthalmology. 2012 May;119(5):1024-32
pubmed: 22440275
Ophthalmol Retina. 2018 Aug;2(8):836-841
pubmed: 30221215
JAMA. 2017 May 23;317(20):2072-2087
pubmed: 28492910
Trans Am Ophthalmol Soc. 2000;98:133-41; discussion 141-3
pubmed: 11190017
PLoS One. 2013 Dec 26;8(12):e82922
pubmed: 24386127
Am J Ophthalmol. 2016 Nov;171:47-52
pubmed: 27567889
JAMA Ophthalmol. 2019 Jan 1;137(1):46-47
pubmed: 30286233
J Thromb Haemost. 2015 Jul;13(7):1254-63
pubmed: 25894549
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3503-3510
pubmed: 30025093
Int J Ophthalmol. 2017 Apr 18;10(4):605-612
pubmed: 28503435
Ophthalmol Retina. 2019 Jan;3(1):83-92
pubmed: 30929820
JAMA Ophthalmol. 2014 Nov;132(11):1309-16
pubmed: 25058813
Ophthalmol Retina. 2018 Nov;2(11):1125-1132
pubmed: 30511035
Br J Ophthalmol. 2013 Mar;97(3):278-84
pubmed: 23298885
Arch Ophthalmol. 1996 Oct;114(10):1243-7
pubmed: 8859084
Ophthalmologica. 2018;240(4):229-234
pubmed: 30089307
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Retina. 2018 Mar;38(3):559-568
pubmed: 28248827
Ophthalmology. 2010 Jun;117(6):1113-1123.e15
pubmed: 20430446